Our Take
Early-stage funding for untested technology in a crowded space where many startups promise to solve solid tumor challenges.
Why it matters
T cell engagers have struggled with solid tumors and dosing limitations. If gamma delta targeting works, it could expand immunotherapy beyond blood cancers.
Do this week
Oncology teams: track CYT X300's Phase I data when it starts to validate gamma delta claims against existing CD3 engagers.
Cytospire closed $83M Series A for gamma delta approach
London-based Cytospire raised £61 million ($83 million) in Series A funding led by 4BIO Capital (per company announcement). The biotech is developing "pan-gamma delta" T cell engagers that target all gamma delta T cells rather than the CD3 receptor used by approved therapies.
The lead program, CYT X300, has not entered human testing. Cytospire plans to test it in EGFR-positive solid tumors including colorectal, head and neck, and non-small cell lung cancers.
CEO Natalie Mount previously led two T cell engager companies acquired by Takeda: Adaptate Biotherapeutics and GammaDelta Therapeutics, where she served as chief scientific officer. Mount is now a venture partner at Abingworth, which led Cytospire's seed round.
Solid tumors remain the key test
Approved T cell engagers work primarily in blood cancers. Companies struggle with solid tumors due to the immunosuppressive tumor microenvironment and dose-limiting side effects that force lower dosing.
Cytospire's thesis: gamma delta T cells already exist within tumor microenvironments and can better distinguish between tumor antigens and healthy cell markers. If true, this could address both penetration and safety issues that limit current engagers.
The space is crowded. Multiple public and private companies are developing alternative T cell engager approaches beyond conventional CD3 targeting.
Wait for human data
No independent validation exists for Cytospire's gamma delta approach. The company's claims about tumor microenvironment penetration and antigen discrimination remain untested in humans.
CYT X300 will need to demonstrate both safety and efficacy advantages over existing EGFR-targeting approaches in its planned solid tumor indications. Phase I data will be the first real test of whether gamma delta targeting delivers on its theoretical advantages.
For oncology teams, the key metric will be whether Cytospire achieves meaningful anti-tumor activity without the dose-limiting toxicities that constrain current T cell engagers in solid tumors.